trending Market Intelligence /marketintelligence/en/news-insights/trending/8purehx6_0_59l8akhqf-a2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Novo Nordisk sued for false availability claims against Sanofi drugs

Streaming Media Devices Feel The Squeeze In Q3'19

AT&T To Use Wireless Subs To Create Buzz For HBO

Municipal CUSIP Requests On Pace For Record Year, Thanks To October Issuance Surge

Creating an Efficient Enterprise Wide Credit Risk Management System for a Leading Energy Company

Novo Nordisk sued for false availability claims against Sanofi drugs

Sanofi filed a lawsuit against Novo Nordisk A/S for allegedly making false claims regarding the availability of Sanofi's insulin drugs for U.S. patients in order to promote its competing drug, Reuters reported Dec. 27.

In a Dec. 23 complaint filed in the U.S. District Court for the District of New Jersey, Sanofi reportedly requested an order to force Novo Nordisk to pay unspecified monetary damages and withdraw marketing materials for its drug Tresiba.

Sanofi stated that Novo Nordisk's marketing materials allegedly urged doctors and patients to switch to Tresiba from Sanofi diabetes drugs Lantus and Toujeo, claiming that the drugs will be blocked by CVS Caremark in January 2017, according to Reuters.

The French drugmaker reportedly stated that the drugs in question are being replaced by Eli Lilly & Co.'s Basaglar on CVS' standard formulary. However, Sanofi noted that several health plans do not use that formulary and the ones using the CVS formulary will likely continue covering the diabetes drugs.

Sanofi provides help in buying the drugs in question in case they are not covered by an individual's insurance, Reuters reported.

Novo Nordisk did not comment on the matter, according to Reuters.